About the project
Despite treatment advances, PDAC has a dismal 5-year survival rate (<7%). The failure to translate the effects of existing therapeutics into better survival benefits for patient with pancreatic ductal adenocarcinoma (PDAC) is mainly linked to the development of treatment resistance.
The experiments are based on primary cultures of human PDAC-derived cancer cells and PSCs and tumor tissue biopsies. In this project, multiomics techniques including genomics, proteomics, metabolomics and lipidomics are employed.
Collaborators
- Lars O. Dragsted, University of Copenhagen, Denmark
- Jan Borén, University of Gothenburg, Sweden
Funding
- University of Oslo
-
South-Eastern Norway Regional Health Authority (HSØ), project nr. 2020062
Study period
- 2018 - ongoing